EUCTR2007-000004-33-IT进行中（未招募）1 期
GR012: A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer - NGR012
MOLMED0 个研究点开始时间: 2007年4月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •?Patients >=18 years old affected by advanced or metastatic ovarian cancer previously treated with platinum regimens (cis or carboplatin) plus paclitaxel and with documented progression disease within 6 months from last chemotherapy administered (refractory/resistant population) or in progression disease after 6 months from last chemotherapy (platinum regimens plus paclitaxel) administered ? Rechallenge with platinum regimens ? No previous exposure to anthracyclines ? Histologically or cytologically confirmed ovarian carcinoma ? Life expectancy more than 3 months ? ECOG Performance status 0 - 1 ? Normal cardiac function (LVEF >=55%) and absence of uncontrolled hypertension ? Measurable disease defined as >=1 unidimentionally measurable lesion >= 20 mm by conventional technics or >= 10 mm ( spiral CT scan or PET); ascites is allowed if present with peritoneal carcinosis ?Adequate baseline bone marrow, hepatic and renal function, defined as follows: neutrophils > 1.5 x 10^9/L and platelets > 100 x 10^9/L; bilirubin < 1.5 x ULN;AST and/or ALT < 2.5 x ULN in absence of liver metastasis;AST and/or ALT < 5 x ULN in presence of liver metastasis;Serum creatinine < 1.5 x ULN ? Absence of any conditions in which hypervolaemia and its consequences or haemodilution could represent a risk for the patient ? Patients must give written informed consent to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Concurrent anticancer therapy ? Patients must not receive any other investigational agents while on study ? New York Heart Association class II-IV cardiac disease ? Acute angina ? Patients with myocardial infarction within the last six (6) months ? Patient with significant peripheral vascular disease ? Thrombosis of main portal vein ? Clinical signs of CNS involvement ? Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol ? Known hypersensitivity/allergic reaction to human albumin preparations or to any of the excipients ? Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol ? Pregnancy or lactation.
研究者
相似试验
进行中（未招募）
不适用
GR010: A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen - NGR010patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeuticMedDRA version: 6.1Level: PTClassification code 10035605EUCTR2006-005993-39-ITMOLMED
进行中（未招募）
不适用
GR007 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic small cell lung carcinoma SCLC previously treated with no more than one therapeutic regimen - NGR007patients affected by advanced or metastatic small cell lung carcinoma SCLC previously treated with no more than one therapeutic regimenMedDRA version: 9.1Level: LLTClassification code 10059514Term: Small cell lung cancer metastaticEUCTR2006-005700-14-ITMOLMED
进行中（未招募）
不适用
GR008 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic hepatocellular carcinoma HCC previously treated with no more than one systemic therapeutic regimen - NGR008EUCTR2006-005696-18-ITMOLMED
进行中（未招募）
不适用
GR006 A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by colorectal cancer CRC , previously treated with fluoropyrimidine, oxaliplatin and irinotecan based regimens. - NGR006Patients affected by advanced or metastatic colorectal cancer CRC.Level: PTClassification code 10061451EUCTR2006-005451-15-ITMOLMED27
进行中（未招募）
不适用
GR018: Randomized study based on administration of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancerAdvanced or metastatic platinum-resistant ovarian cancer patientsEUCTR2012-005745-20-ITMolMed S.p.A.24